Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Allergy Therapeutics PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Total Current Liabilities
ÂŁ25.3m
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
15%
GlaxoSmithKline PLC
LSE:GSK
Total Current Liabilities
ÂŁ20.3B
CAGR 3-Years
-2%
CAGR 5-Years
-5%
CAGR 10-Years
5%
AstraZeneca PLC
LSE:AZN
Total Current Liabilities
$28.6B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Current Liabilities
$28m
CAGR 3-Years
0%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Current Liabilities
$1.4B
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
9%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Current Liabilities
ÂŁ164m
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
5%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Total Current Liabilities?
Total Current Liabilities
25.3m GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Total Current Liabilities amounts to 25.3m GBP.

What is Allergy Therapeutics PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
15%

Over the last year, the Total Current Liabilities growth was 48%. The average annual Total Current Liabilities growth rates for Allergy Therapeutics PLC have been 16% over the past three years , 13% over the past five years , and 15% over the past ten years .

Back to Top